[18F]F-AraG

DRUG4 trials

Sponsors

CellSight Technologies, Inc.

Conditions

Advanced Non Small Cell Lung CancerCancerCorrelate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

Phase 1

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

CompletedNCT02323893

CellSight Technologies, Inc.Cancer

Start: 2015-02-28End: 2017-12-31Updated: 2018-05-17

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

CellSight Technologies, Inc.Cancer

Start: 2017-05-01End: 2024-05-31Target: 30Updated: 2022-12-05

Phase 2

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

TerminatedNCT04260256

CellSight Technologies, Inc.Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

Start: 2022-03-01End: 2026-03-01Updated: 2026-03-27

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

RecruitingNCT06107374

CellSight Technologies, Inc.Advanced Non Small Cell Lung Cancer

Start: 2023-11-01End: 2026-03-31Target: 20Updated: 2024-10-24